NEW YORK, May 27, 2026, 06:05 (EDT)
- NUWE dropped 13.61% to close at $0.9071 on Tuesday, then was seen at $0.8903 before the market opened Wednesday.
- A filing on May 22 shows up to 4.85 million common shares or pre-funded warrants, along with Series C and Series D warrants included in the S-1.
- Nuwellis posted first-quarter net sales of $2.4 million, a 26% increase. Cash, cash equivalents and restricted cash stood at about $2.2 million as of March 31.
Nuwellis Inc. shares looked set to drop again in early U.S. trading Wednesday, after tumbling Tuesday. The small medical-device maker filed a preliminary registration statement for an equity offering packed with warrants.
S-1 clearance hit after Friday’s close. With the SEC’s move late Friday, investors had to wait out the Memorial Day break before trading on Tuesday. Shares of NUWE slid 13.61% that session and dropped 1.85% more pre-market Wednesday.
Nuwellis filed to offer up to 4,854,369 shares of common stock, or the same number of pre-funded warrants, each with a Series C and Series D warrant attached. The filing notes warrants give holders a right to buy shares later, which can lead to dilution if exercised. The company figures net proceeds could reach around $4.4 million if everything sells at $1.03 per share. There’s no minimum sale needed for the deal to go through.
Dilution risk is in focus right now. Nuwellis said its common stock count would jump to 7.49 million after the offering, if all pre-funded warrants get exercised. That doesn’t include the common and placement-agent warrants. The company had 2.64 million shares out as of March 31. The registration statement also covers as many as 14.71 million shares tied to exercise of the pre-funded, Series C, Series D, and placement-agent warrants.
Nuwellis, out of Eden Prairie, Minnesota, makes the Aquadex SmartFlow system for ultrafiltration. That’s used to remove extra fluid when diuretics and other standard treatments don’t work, the company said. Nuwellis trades on the Nasdaq Capital Market as NUWE.
Nuwellis moved to raise capital after the latest quarter brought higher sales but tight margins. The company posted first-quarter revenue of $2.4 million, up from $1.9 million last year. Gross margin hit 70.1%. Net loss attributable to common shareholders was about $4.3 million. CEO John Erb said the quarter suggested the 2025 reset was making the company “more focused and commercially disciplined.”
Nuwellis still has a product story running under the financing. On May 14, the company said it finished an FDA pre-submission meeting for a possible Aquadex label expansion to include pediatric patients as small as 5 kg, lower than the current 20 kg cutoff. A 510(k) is the standard U.S. device filing to show a product matches an already-cleared device.
Stuart Goldstein, director of clinical strategy at Nuwellis, said fluid management for low-weight pediatric patients is “highly sensitive.” Kelsey Newell, the company’s senior director of medical affairs, said its approach brings together clinical experience and “real-world evidence.” Stock Titan
Nuwellis, in its filing, said there aren’t direct U.S. rivals to Aquadex for heart failure or critical care besides diuretics. It named Baxter’s Prismaflex and Carpediem, which is distributed by Medtronic, as relevant in renal replacement or pediatric uses.
Nuwellis shares are acting like a distressed micro-cap. StockAnalysis says the company’s market cap is around $2.39 million, with shares losing 97.67% over the past year. The last reverse split was 1-for-42 in July 2025.
Nuwellis spelled out the risks in its filing. The company said it only has enough cash to run operations through the end of the second quarter of 2026, and it’s now trying to raise more to get through year-end. If it can’t find new capital, Nuwellis said it could have to slow down, cut back, or even halt operations. Shares could stay under pressure if the offering price is low, demand is weak, or if FDA progress remains slow.
Investors looking at NUWE are focused on three things: the pricing and effectiveness of the current offering, if the company can sell enough securities before the June 30 S-1 termination, and the expected FDA filing for its pediatric Aquadex label before the end of 2026. NUWE shares are moving mainly on capital structure news, not the wider market.
